Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -22.47 Million EUR | -4.98% |
| 2022 | -21.4 Million EUR | -8.65% |
| 2021 | -19.7 Million EUR | -1.45% |
| 2020 | -19.42 Million EUR | -164.46% |
| 2019 | -7.34 Million EUR | -269.62% |
| 2018 | -1.98 Million EUR | -308.75% |
| 2017 | -486.11 Thousand EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -6.52 Million EUR | -6.57% |
| 2024 Q2 | -6.51 Million EUR | 4.09% |
| 2023 Q3 | -5.1 Million EUR | 16.4% |
| 2023 Q1 | -5.14 Million EUR | 5.19% |
| 2023 Q4 | -6.12 Million EUR | -20.0% |
| 2023 FY | -22.47 Million EUR | -4.98% |
| 2023 Q2 | -6.1 Million EUR | -18.53% |
| 2022 Q3 | -4.79 Million EUR | 20.96% |
| 2022 FY | -21.4 Million EUR | -8.65% |
| 2022 Q4 | -5.43 Million EUR | -13.19% |
| 2022 Q2 | -6.07 Million EUR | -18.74% |
| 2022 Q1 | -5.11 Million EUR | 5.22% |
| 2021 Q1 | -4.36 Million EUR | 5.78% |
| 2021 Q3 | -5.1 Million EUR | -5.52% |
| 2021 Q4 | -5.39 Million EUR | -5.59% |
| 2021 Q2 | -4.84 Million EUR | -10.98% |
| 2021 FY | -19.7 Million EUR | -1.45% |
| 2020 FY | -19.42 Million EUR | -164.46% |
| 2020 Q4 | -4.62 Million EUR | -21.64% |
| 2020 Q3 | -3.8 Million EUR | 42.52% |
| 2020 Q2 | -6.62 Million EUR | -51.71% |
| 2020 Q1 | -4.36 Million EUR | -67.29% |
| 2019 Q1 | -1.08 Million EUR | 0.0% |
| 2019 Q4 | -2.6 Million EUR | -25.93% |
| 2019 FY | -7.34 Million EUR | -269.62% |
| 2019 Q3 | -2.07 Million EUR | -31.22% |
| 2019 Q2 | -1.57 Million EUR | -45.8% |
| 2018 FY | -1.98 Million EUR | -308.75% |
| 2017 FY | -486.11 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biohit Oyj | 1.82 Million EUR | 1331.538% |
| Herantis Pharma Oyj | 154.36 Thousand EUR | 14659.729% |